World Journal of Surgical Oncology Gastrointestinal Stromal Tumors: Correlation between Symptoms at Presentation, Tumor Location and Prognostic Factors in 47 Consecutive Patients

Gastrointestinal stromal tumors: correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients Caterino et al. Abstract Background: Gastrointestinal stromal tumors (GIST) are mesenchymal tumors of the gastrointestinal tract, usually kit-positive, that are believed to originate from interstitial cell of Cajal, or their related stem cells. The most common clinical presentation of these tumors is gastrointestinal bleeding, otherwise they may cause intestinal obstruction, abdominal pain, a palpable mass, or can be incidentally detected during surgery or endoscopic/ radiological procedures. Prognosis is related to the size of the tumor and to the mitotic rate; other prognostic factors are tumor location, tumor resection margins, tumor rupture, and c-kit mutation that may interfere with molecular target therapy efficacy.

[1]  C. Messiou,et al.  Soft Tissue Sarcomas , 2020, Treatment of Cancer.

[2]  R. Lunevicius,et al.  Gastrointestinal stromal tumor. , 2012, Journal of gastrointestinal oncology.

[3]  I. Espinosa,et al.  The Utility of Discovered on Gastrointestinal Stromal Tumor 1 (DOG1) Antibody in Surgical Pathology—the GIST of It , 2010, Advances in anatomic pathology.

[4]  C. Antonescu,et al.  NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  W. Young,et al.  Gastric Stromal Tumors in Carney Triad Are Different Clinically, Pathologically, and Behaviorally From Sporadic Gastric Gastrointestinal Stromal Tumors: Findings in 104 Cases , 2010, The American journal of surgical pathology.

[6]  Xiaoting Wu,et al.  Synchronous incidental gastrointestinal stromal and epithelial malignant tumors. , 2009, World journal of gastroenterology.

[7]  H. Joensuu.  Risk stratification of patients diagnosed with gastrointestinal stromal tumor. , 2008, Human pathology.

[8]  P. Rutkowski,et al.  Developments in targeted therapy of advanced gastrointestinal stromal tumors. , 2008, Recent patents on anti-cancer drug discovery.

[9]  M. Schlemmer,et al.  Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  S. Parsons,et al.  Gastrointestinal stromal tumours (GIST) - 17 years experience from Mid Trent Region (United Kingdom). , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  J. Fletcher,et al.  Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Uppin,et al.  Gastrointestinal stromal tumors: a single institution experience of 50 cases. , 2007, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

[13]  A. D. Van den Abbeele,et al.  NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[14]  H. Earl,et al.  RECIST and Choi criteria for response assessment (RA) in patients with inoperable and metastatic gastrointestinal stromal tumours (GISTs) on imatinib mesylate. Cambridge GIST study group experience , 2007 .

[15]  P. Casali,et al.  Surgery of Residual Disease Following Molecular-targeted Therapy With Imatinib Mesylate in Advanced/Metastatic GIST , 2007, Annals of surgery.

[16]  J. Lasota,et al.  Gastrointestinal stromal tumors: pathology and prognosis at different sites. , 2006, Seminars in diagnostic pathology.

[17]  Corrado Ficorella,et al.  Raccomandazioni cliniche per la diagnosi, la terapia ed il follow-up dei tumori stromali gastrointestinali. , 2006 .

[18]  E. Wardelmann,et al.  Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate , 2006, Clinical Cancer Research.

[19]  E. Musulen,et al.  Gastrointestinal stromal tumors , 2006, Abdominal Imaging.

[20]  J. Jónasson,et al.  Gastrointestinal stromal tumors in Iceland, 1990–2003: The Icelandic GIST study, a population‐based incidence and pathologic risk stratification study , 2005, International journal of cancer.

[21]  I. Gouda,et al.  Gastrointestinal stromal tumor (GIST)'s surgical treatment, NCI experience. , 2005, Journal of the Egyptian National Cancer Institute.

[22]  Y. Kitamura,et al.  Kit as a human oncogenic tyrosine kinase. , 2004, Cellular and molecular life sciences : CMLS.

[23]  S. Bonvalot,et al.  Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[24]  J. Blay,et al.  Gastrointestinal Stromal Tumors: Biology and Treatment , 2003, Oncology.

[25]  C. Fisher,et al.  Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. , 2003, Radiology.

[26]  R. DeMatteo.  The GIST of targeted cancer therapy: A tumor (Gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571) , 2002, Annals of Surgical Oncology.

[27]  Markku Miettinen,et al.  Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. , 2002, European journal of cancer.

[28]  Tony Pawson,et al.  Regulation and targets of receptor tyrosine kinases. , 2002, European journal of cancer.

[29]  L. Sobin,et al.  Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.

[30]  C. J. Chen,et al.  KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.

[31]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[32]  B. Yeap,et al.  The effect of surgery and grade on outcome of gastrointestinal stromal tumors. , 2001, Archives of surgery.

[33]  Robert H Lyles,et al.  Extragastrointestinal (Soft Tissue) Stromal Tumors: An Analysis of 48 Cases with Emphasis on Histologic Predictors of Outcome , 2000, Modern Pathology.

[34]  D. Driscoll,et al.  An institutional review of sarcomas of the large and small intestine. , 1995, Journal of the American College of Surgeons.

[35]  P. Chow,et al.  Which Is the Optimal Risk Stratification System for Surgically Treated Localized Primary GIST ? Comparison of Three Contemporary Prognostic Criteria in 171 Tumors and a Proposal for a Modified Armed Forces Institute of Pathology Risk Criteria , 2008 .

[36]  J. Donohue,et al.  Surgically Managed Gastrointestinal Stromal Tumors: A Comparative and Prognostic Analysis , 2007, Annals of Surgical Oncology.

[37]  Anastasios Stofas,et al.  World Journal of Surgical Oncology , 2007 .

[38]  H. Yamaue,et al.  Surgical Management of Small Gastrointestinal Stromal Tumors of the Stomach , 2005, World Journal of Surgery.

[39]  J. Lasota,et al.  Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis , 2000, Virchows Archiv.

[40]  R. DeMatteo,et al.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.

[41]  L. Sobin,et al.  Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. , 1999, The American journal of surgical pathology.